Gilead Sciences, Inc.

Cv Therapeutics, Inc.

Gilead Palo Alto, Inc.

Dewan Zeng

Luiz Belardinelli

Charles Antzelevitch

John Shryock

Alexander Burashnikov

Hongyan Zhong

Jeff A Zablocki

Rao V Kalla

Michael R Blackburn

Sridharan Rajamani

Described herein is a method of treating long QT syndrome by administration of an effective amount of a potent and selective late sodium ion channel blocker.

Compound and methods for treating long QT syndrome

The present invention relates to a method for the treatment or prevention of atrial fibrillation and/or atrial flutter comprising coadministration of a synergistically therapeutic amount of dronedarone or a pharmaceutically acceptable salt or salts thereof and a synergistically therapeutic amount of ranolazine or a pharmaceutically acceptable salt or salts thereof. Also provided are methods for modulating ventricular and atrial rhythm and rate. This invention also relates to pharmaceutical formulations that are suitable for such combined administration.

Method of treating atrial fibrillation

The invention is related to methods of inhibiting hepatic fibrosis using Aadenosine receptor antagonists and utility in the treatment and prevention of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases. The invention also relates to pharmaceutical compositions for use in the method.

[object Object]

The present invention relates to methods of preventing airway remodeling using Aadenosine receptor antagonists. This invention finds utility in the treatment and prevention of asthma, COPD, pulmonary fibrosis, emphysema, and other pulmonary diseases. The invention also relates to pharmaceutical compositions for use in the method.

The invention is related to a method of decreasing hepatotoxic side effects using an A2B adenosine receptor antagonist and utility in the treatment of liver damage caused by undergoing hepatotoxic treatment, such as chemotherapy or radiation. The invention also relates to pharmaceutical compositions for use in the method.

The invention is related to methods of treating hepatic fibrosis using Aadenosine receptor antagonists and utility in the treatment of liver damage caused by alcohol abuse, surgical intervention, viral hepatitis, the ingestion of hepatotoxic drugs, or other hepatic diseases.

Disclosed are novel methods of antagonizing the Aadenosine receptor in a mammal, comprising administering to a mammal in need thereof a therapeutically effective dose of a compound of the formula:wherein Ris optionally substituted Calkyl; Y is Calkylene; and Z is phenyl that is optionally substituted with halo, hydroxy, amino, cyano, or optionally substituted Calkyl or a pharmaceutically acceptable salt, ester, or prodrug thereof. The Aadenosine receptors are antagonized in order to treat a disease state is chosen from renal failure, renal dysfunction, nephritis, hypertension, edema, Alzheimers disease, stress, depression, cardiac arrhythmia, restoration of cardiac function, congestive heart failure, diabetes, asthma, respiratory disorders, ischemia-induced injury of the brain, heart and kidney, and diarrhea.

Growing community of inventors

Palo Alto, CA, United States of America

Dewan Zeng